SteroTherapeutics (Philadelphia, PA) is Philadelphia based biopharmaceutical company pursuing treatments for Cushing’s syndrome and non-alcoholic steatohepatitis (NASH). Company's lead candidate is a novel anti-glucocorticoid and G6PD inhibitor that has been studied in >100 patients. SteroTherapeutics received orphan designation for ST-002 for the treatment of hyperglycemia, Non-Alcoholic Fatty Disease (NAFLD) and NASH in Cushing’s syndrome patients. ST-001 is in development for Non-alcoholic steatohepatitis (NASH) which has been predicted as the next major health epidemic.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):